Trial Profile
BOOG 2017-03: Endocrine Therapy Plus CDK 4/6 Inhibition in First- or Second-line for Hormone Receptor Positive Advanced Breast Cancer - the SONIA Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary) ; 18F-fluoroestradiol; Anastrozole; Estradiol dehydrogenase inhibitors; Fulvestrant; Goserelin; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Oxacillin; Oxacillin
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms SONIA
- 06 Jun 2023 Primary endpoint PFS2 has not been met according to result presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results (data cut off 1 December 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 27 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2025.